Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biofrontera Inc (BFRI) Fair Value & Analysis

Healthcare · US · Market cap $12.7M

Price$0.9999
Fair Value$0.5500
Upside-45.0%
Quality95/100
Evidence: Low Range $0.4100 – $0.8200

Fair value as of: Jun 25, 2026

Analysis

Biofrontera Inc (BFRI) currently trades at $0.9999, while our model-based Fair Value estimate is $0.5500 — implying the stock looks roughly 45.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Biofrontera Inc (BFRI) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.5500 versus a price of $0.9999 — about −45% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BFRI?
Our 21-model fair value for Biofrontera Inc is $0.5500 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.9999.
What is the quality score of BFRI?
Biofrontera Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.